ReviewLancet (London, England)2015
Lewy body dementias.
Review in Lancet (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 262 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
262 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Frontotemporal dementia: a systematic review of artificial intelligence approaches in differential diagnosis.Frontiers in aging neuroscience · 2025Pooled it
- Neuroanatomical and clinical correlates of prodromal dementia with Lewy bodies: a systematic literature review of neuroimaging findings.Journal of neurology · 2024Pooled it
- Air pollution: a latent key driving force of dementia.BMC public health · 2024Pooled it
- The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.The Cochrane database of systematic reviews · 2021Pooled it
- Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis.European journal of nuclear medicine and molecular imaging · 2020Pooled it
- Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.Movement disorders : official journal of the Movement Disorder Society · 2022Trial
- VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies.International journal of molecular sciences · 2019Trial
- Dorsal and ventral stream visuoperceptual processing deficits in Lewy body disease.Journal of neurology · 2026Article
- Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics.JAMA network open · 2026Article
- Language network disruption in patients with Lewy body diseases.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Understanding the genetic imperfections of Lewy body dementia.Molecular neurodegeneration · 2026Review
- Clinical and literature insights into the frontotemporal dementia and motor neuron disease spectrum.Discover mental health · 2026Article
- Role of α-Synuclein in the Prefrontal Cortex: From Physiological Synaptic Modulation to Synaptic Failure in Parkinson's Disease.Biomedicines · 2026Review
- Spontaneous Isomerization of Tau is Most Prevalent in Alzheimer's Disease.NeuroMarkers · 2026Article
- Article
- Self-reporting quality of life in mild-to-moderate Alzheimer's disease and Lewy body dementia: Comparing capability and health-focused measures using response process validation.Social science & medicine (1982) · 2026Article
- Patients' and care partners' views on communicating the cause of dementia and related uncertainties: A qualitative study.Journal of Alzheimer's disease : JAD · 2026Article
- Global and domain-specific cognitive intraindividual variability associations with neurodegenerative diagnoses and postmortem pathologies.Alzheimer's research & therapy · 2026Article
- Distinct associations between body mass index and polyunsaturated fatty acids in dementia with Lewy Bodies and Alzheimer's disease.The journal of nutrition, health & aging · 2026Article
202 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting the most attention. However, dementia with Lewy bodies and Parkinson's disease dementia, now called Lewy body dementias, are the second most common type of degenerative dementia in patients older than 65 years. Despite this, Lewy body dementias receive little attention and patients are often misdiagnosed, leading to less than ideal management. Over the past 10 years, considerable effort has gone into improving diagnostic accuracy by refining diagnostic criteria and using imaging and other biomarkers. Dementia with Lewy bodies and Parkinson's disease dementia share the same pathophysiology, and effective treatments will depend not only on successful treatment of symptoms but also on targeting the pathological mechanisms of disease, ideally before symptoms and clinical signs develop. We summarise the most pertinent progress from the past 10 years, outlining some of the challenges for the future, which will require refinement of diagnosis and clarification of the pathogenesis, leading to disease-modifying treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.